• Novel Biochemical and Molecular Determinants for Soft Tissue Sarcoma

  NCT00579566

  RecruitingObservationalUpdated Jul 30, 2026
• Molecular Profiling of Advanced Soft-tissue Sarcomas

  NCT03784014

  CompletedInterventionalPhase 3Updated Apr 29, 2026
• Observational Study, for Quality Assessment, of Sarcoma in European and Latin American Multidisciplinary NETWORK

  NCT04181970

  RecruitingObservationalUpdated Mar 21, 2025
• MASCT-I Combined With Doxorubicin and Ifosfamide for First-line Treatment of Advanced Soft Tissue Sarcoma

  NCT06277154

  RecruitingInterventionalPhase 2Updated Jul 24, 2025
• Blood and Tissue Extraction for Immunological Examinations During Neoadjuvant Therapy of Soft Tissue Sarcomas

  NCT06385288

  RecruitingInterventionalNot ApplicableUpdated Dec 6, 2024
• Study Evaluating the Safety and Efficacy of MEDI5752 in Combination With Stereotactic Radiotherapy in Patients With Metastatic Sarcoma

  NCT05821231

  Active, not recruitingInterventionalPhase 1Updated Jul 31, 2025

ClinicalTrials.gov ID

NCT03967834

Lead Sponsor

Institut Claudius RegaudOTHER

Overall Status

Recruiting

Study Type

Interventional

Phase

Not Applicable

Enrollment

400Estimated

Last Update Posted

Feb 10, 2026Actual

Start Date

Apr 26, 2021Actual

Primary Completion Date

Apr 2031Estimated

Completion Date

Apr 2031Estimated

Official Title

Multimodal Immune Characterization of RAre Soft Tissue Sarcoma - MIRAS Project From SARRA (SARcome RAre) Project of the French Sarcoma Group

Brief Summary

This trial is a translational, open-label, multi-sites, prospective and retrospective cohort study of 500 patients aimed at clinical and biological characterization of sarcoma of rare subtype.

400 patients will be included in this prospective cohort study; they will be identified in the investigating centers in the context of either routine care or a clinical study protocol.

Retrospective cases of patients (100 cases in total) will be identified in all centers through the GSF/GETO clinical databases already setted up (including the clinical base Conticabase).

• Soft Tissue Sarcoma
• Clear Cell Sarcoma
• Epithelioid Sarcoma
• Perivascular Epithelioid Cell Neoplasms
• Desmoplastic Small Round Cell Tumor
• Malignant Solitary Fibrous Tumors
• Alveolar Soft Part Sarcoma
• Epithelioid Hemangioendothelioma
• Low Grade Fibromyxoid Sarcoma
• Sclerosing Epithelioid Fibrosarcoma

• Patient with Soft Tissue Sarcoma

Ages Eligible for Study

Adult (18-64)Older Adult (65+)

Sexes Eligible for Study

All

Accepts Healthy Volunteers

No

Eligibility Criteria

Inclusion Criteria:

1. Age ≥18 years at the time of study entry.

2. Diagnosis of one of the following rare sarcoma subtype, confirmed by RRePS network:

   • Clear Cell Sarcoma (CCS)
   • Epithelioid Sarcoma (ES)
   • Perivascular Epithelioid Cell neoplasm (PEComa)
   • Desmoplastic Small Round Cell Tumours (DSRCT)
   • Malignant Solitary Fibrous Tumours (mSFT)
   • Alveolar Soft Part Sarcoma (ASPS)
   • Epithelioid Hemangioendothelioma (EH)
   • Low-Grade Fibromyxoid Sarcoma (LGFS)
   • Sclerosing Epithelioid Fibrosarcoma (SEF).

3. Localized/locally advanced or metastatic disease.

4. In case of localized disease, treatment must not have been yet initiated before inclusion (except surgical excision).

5. In case of metastatic disease, project of new line of systemic treatment must have been decided before inclusion.

6. Patient followed in the center within a standard of care procedure or clinical trial.

7. Archived tumor specimen at initial diagnosis available (before treatment initiation).

8. Evaluable disease (measurable as per RECIST 1.1) or not.

9. ECOG Performance status 0-3.

10. Patient able to participate and willing to give informed consent prior to performance of any study-related procedures.

11. Patient affiliated to a Social Health Insurance in France.

Exclusion Criteria:

1. Diagnosis of all other histotypes of soft tissue sarcoma.
2. Any condition contraindicated with procedures required by the protocol.
3. Known history of positive test for hepatitis B virus or hepatitis C virus or human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS).
4. Any psychological, familial, geographic or social situation, according to the judgment of investigator, potentially preventing the provision of informed consent or compliance to study procedure.
5. Pregnant or breast-feeding woman.
6. Patient who has forfeited his/her freedom by administrative or legal award or who is under guardianship.

Primary Purpose

Other

Allocation

N/A

Interventional Model

Single Group Assignment

Masking

None (Open Label)

Lead Sponsor

Institut Claudius RegaudOTHER

valerie.lebrunly@chu-limoges.fr05 55 05 61 00

sarah.watson@curie.fr

nicolas.isambert@chu-poitiers.fr05 49 44 45 48